Astria Therapeutics Reports Positive Phase 1a Trial Results for STAR-0310 in Atopic Dermatitis at European Dermatology & Venereology Congress

Astria Therapeutics reported positive phase 1a trial results for STAR-0310, a monoclonal antibody OX40 antagonist for atopic dermatitis, at the European Dermatology & Venereology Congress. The trial demonstrated the drug's safety and tolerability, with no serious adverse events or dose-limiting toxicities. The results support further development of STAR-0310 for the treatment of atopic dermatitis.

Astria Therapeutics reported positive phase 1a trial results for STAR-0310, a monoclonal antibody OX40 antagonist, at the European Dermatology & Venereology Congress. The trial demonstrated the drug's safety and tolerability, with no serious adverse events or dose-limiting toxicities observed. These findings support further development of STAR-0310 for the treatment of atopic dermatitis (AD).

AD, more commonly known as eczema, is a prevalent chronic skin condition affecting 15-20% of children and up to 10% of adults ABCL575 | AbCellera^[1]. Despite its high prevalence, moderate-to-severe AD remains challenging to treat, with more than half of all patients having inadequate control of symptoms with existing treatments . Recent insights into the underlying source of skin inflammation have led to the development of more targeted treatments, such as biologics. However, a significant number of patients show limited response or discontinuation of these therapies, warranting a need for alternative treatment options .

STAR-0310 targets OX40L, a ligand that plays a key role in inflammatory pathways. By disrupting OX40/OX40L signaling, STAR-0310 has shown potent inhibition of T cell-mediated inflammatory pathways in preclinical studies . The phase 1a trial, initiated in Q3 of 2025, assessed the safety and tolerability of STAR-0310 in healthy participants following subcutaneous doses. The positive results indicate that STAR-0310 may offer a promising alternative for the treatment of moderate-to-severe AD.

The successful completion of phase 1a trials is a significant milestone for Astria Therapeutics, as it paves the way for further clinical development and potential market entry. The company's focus on targeted immunotherapies positions it well to address unmet medical needs in the treatment of inflammatory and autoimmune conditions.